Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Synthesis and characterization of novel substituted spiro[isobenzofuran-1(3H),9’-xanthene]-3-ones

Autor: SACHIN V. PATEL, MANISH P. PATEL, RANGAN G. PATEL

Publikováno v: Journal of the Serbian Chemical Society, Vol 70, Iss 7, Pp 931-936 (2005)

The ketoacid, 2-(4-diethylamino-2-hydroxybenzoyl)benzoic acid, prepared from N,N-diethyl-m-aminophenol and phthalic anhydride, was reacted with various substituted 3-[6-methoxybenzothiazol-2-yl]-4(3H)-quinazolinones in the presence of a dehydration c

Externí odkaz: https://doaj.org/article/35fc16bc332e4c71a4f1b53cc355a311

Establishing a core outcome set for autosomal dominant polycystic kidney disease : report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD) consensus workshop

Autor: Cho, Y., Tong, A., Craig, J.C., Mustafa, R.A., Chapman, A., Perrone, R.D., Ahn, C., Fowler, K., Torres, V., Gansevoort, R.T., Ong, A.C.M., Coolican, H., Tze-Wah Kao, J., Harris, T., Gutman, T., Shen, J.I., Viecelli, A.K., Johnson, D.W., Au, E., El-Damanawi, R., Logeman, C., Ju, A., Manera, K.E., Chonchol, M., Odland, D., Baron, D., Pei, Y., Sautenet, B., Rastogi, A., Sharma, A., Rangan, G.

The omission of outcomes that are of relevance to patients, clinicians and regulators across trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision-making. The Standardized Outcomes in Nephrology – Polycystic Kidney D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::7b0cd65597b0bb7ced84a9c6bdcef9b3
https://eprints.whiterose.ac.uk/164533/1/SONGPKD_Workshop_AJKD_2020ccepted.pdf

WCN23-0047 ASSOCIATION OF CLIMATE ON END STAGE KIDNEY FAILURE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN AUSTRALIA: A 30-YEAR DATABASE STUDY

Autor: NGUYEN, A., Sud, K., Rangan, G., Au, E., Vincent W.S, L.

Publikováno v: In Kidney International Reports March 2023 8(3) Supplement:S283-S284

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Autor: Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Tempo team, Gross P, Schulze B, Bichet D, Chauveau D, Peeters P, Voiculescu M, Manunta P, Tuazon J, Watnick T, Goral S, Horie S, Nutahara K, Torres V, Chapman A, Gansevoort R, Perrone R, Czerwiec F, Goldstein S, Cowley B, Fukagawa M, Torra R, Wei LJ, Cook T, Toto R, Agarwal R, August P, Bakris G, Beddhu S, Corwin H, Ruilope L, Rosa-Diez G, De La Fuente J, Martin R, Massari P, Novoa P, Rial M, Wasserman A, Faull R, Fraser I, Johnson D, Pedagagos E, Lian M, Pollock C, Cooper B, Rangan G, Russ G, McDonald S, Thomas M, Khoo D, Walker R, Pirson Y, Laecke V, Van der Niepen P, Sennesael J, Barre P, Alam A, Soroka S, Dieperink H, Strandgaard S, Petersen L, Berthoux F, Canaud B, Gontiers-Picard A, Huart A, Combe C, Delmas Y, Dussol B, Laville M, Guebre-Egziabher F, Mignon F, Michel C, Rieu P, Noel N, Ryckelynck J, Lobbedez T, Dellanna F, Kleophas W, Feldkamp T, Witzke O, Nurnberger J, Zeltner R, Walz G, Zeier M, Sommerer C, Bianchi S, Capasso G, Miranda N, Magistroni R, Bracale M, Remuzzi G, Rota S, Villa G, Tilocca P, Asahi K, Kato T, Endo M, Umezono T, Fujigaki Y, Kato A, Fukatsu A, Hasegawa H, Tayama Y, Hasegawa M, Hosoya T, Hanaoka K, Iehara N, Iino Y, Tsuruoka S, Imai E, Isaka Y, Ishimura E, Ito S, Sato H, Kamata K, Sakamoto H, Kamura K, Kusano E, Muto S, Kuwahara M, Matsubara A, Yorioka N, Mochizuki T, Narita I, Naya Y, Nihei N, Yukio N, Nishio S, Nitta K, Tsuchiya K, Okamura M, Sasaki S, Rai T, Seta K, Sugawara A, Shibazaki S, Sugiyama S, Tabei K, Takaichi K, Tomita K, Kitamura K, Tsukamoto Y, Tsuruya K, Nakano T, Ubara Y, Watanabe T, Yamamoto T, Yoshida K, Ishii D, Yuzawa Y, Meijer E, Vervloet M, Ciechanowski K, Wisniewska M, Gutowska-Jablonska M, Marcinkowska-Królewicz M, Klatko W, Wiśniewski T, Klinger M, Krajewska M, Ksiazek A, Orłowska G, Malecki R, Gontarek-Kacprzak J, Nowicki M, Makówka A, Rutkowski B, Wołyniec W, Rydzewski A, Sulowicz W, Jasik P, Covic A, Volovat C, Mircescu G, Petrescu L, Bobeica R, Barbarash O, Chesnokova L, Borovoy S, Demina L, Shostka G, Idovu M, Tkalich L, Geynits O, Tomilina N, Foggensteiner L, Holt S, Kingswood J, Lambie S, Peel R, MacDougall I, Tucker B, MacPhee I, Maxwell A, Brown H, Mikhail A, Bastin L, Turner N, Neary J, Wheeler D, Maxwell P, Wilkie M, Ong A, Zehnder D, Aldridge N, Adler S, Klein M, Battle D, Bennett W, Berger B, Dell K, Blumenfeld J, Donahue S, Bolin P, Browder R, Perry A, Oskoui F, Culpepper M, Dahl N, Edelstein C, Clegg L, Fischer D, Kaplan M, Kaveh K, Pankhaniya R, Koren M, Mansur K, Lafayette R, Lamar W, Lee J, Mahnensmith R, Nachman P, Mottl A, Miskulin D, Petersen J, Radhakrishnan J, Roppolo M, Basireddy M, Rosner M, Bolton W, Schulman G, Steed L, Steinman T, Hogan M, Venuto R, Turban S, Winklhofer F.

Publikováno v: New England Journal of Medicine, 367(25), 2407-2418. MASSACHUSETTS MEDICAL SOC

BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V 2 -receptor antagonists inhibit cyst growth and slow the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c380510d69acd55a125b76c7265afc
https://research.rug.nl/en/publications/8359ee34-e6c2-468d-9dc9-a300699802f3